Vetoquinol - Universal Registration Document - 2021

1 PRESENTATION OF THE GROUP Vetoquinol, your trusted animal health partner 8 Vetoquinol Universal Registration Document 2020 Financial report Implementation of new “In Motion” strategic plan focused on three priorities: capitalizing on the Group’s strong human potential, innovating in bio-technology and customer solutions, and consolidating our multi-specialist strategy. Upgrading of production facilities by adding a major extension to the injectables production unit on the Group’s main production complex in Magny-Vernois. • March 22 nd : acquisition of Austria-based VetCom Pharma, thus boosting Vetoquinol’s range of reproduction products for cattle and pigs. Vetoquinol receives two awards: • ranked 3 rd in the “Mid-Cap Corporate Governance” category at the 14 th Agefi Grands Prix Awards; • Ranked 2 nd in the 2017 Gaia Index for ongoing commitment to corporate social responsibility (CSR). • September 27 th : Vetoquinol organizes an “Investor Day” in Paris to share its strategy with the analyst and investor community. • November 13 th : Vetoquinol acquires a stake in Plant Advanced Technologies (PAT), an investment in line with the Group’s innovation strategy: PAT works on molecules of natural origin that are a potential alternative source of active ingredients for our future veterinary drugs. • Vetoquinol and Orion Pharma Animal Health sign a distribution partnership. • Launch of a new Essentials product, Upcard ® , an innovative drug for congestive heart failure in dogs. • Vetoquinol and Nippon Zenyaku Kogyo Co. Ltd sign an agreement on a joint venture in Japan. • Vetoquinol creates a new brand identity symbolized by a new logo and a single slogan: “Achieve More Together”. 2015 • Creation of an R&D center in the USA designed to step up the development of pet products for the world’s largest animal health market. • Launch of Cimalgex ® in Brazil: first Group Essentials product on the Brazilian pet market. • Relocation of Folltropin ® production to the main Vetoquinol facility in Canada. • Launch of two Essentials products in China: Marbocyl P and Tolfedine. • Magny-Vernois plant ISO 50001-certified: 1 st veterinary pharmaceutical laboratory to obtain this certification. • 10 years of stock trading, quality and transparency of financial reporting recognized. • Vetoquinol ranked equal first (with TF1) in the Gaia Index of small to medium-sized companies for its commitment to corporate social responsibility (CSR) and outright leader in the category of companies with sales between €150 and €500 million. 2016 2017 • New milestone for Vetoquinol in China: obtaining GSP status “Good Selling Practice” license required for distributing veterinary pharmaceuticals in China. • Launch of Forcyl ® in Brazil: first Group Essentials product on the Brazilian pet market. • Acquisition of Bioniche Animal Health, a major supplier of reproduction products in North America. The Vetoquinol offering expands with new flagship products in the domain of reproduction. • Launch of Tolfine in India: first Group Essentials product on the cattle market in India. 2014